These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17201184)

  • 1. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
    Takeyama H; Mohri N; Mizuno I; Akamo Y; Sawai H; Manabe T; Yotsuyanagi T; Nakamura S
    Anticancer Res; 2006; 26(6B):4603-6. PubMed ID: 17201184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
    Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis].
    Ueda T; Mizuno I; Mohri N; Akamo Y; Terada J; Shibata T; Yamamoto T; Takeyama H; Manabe T; Yotsuyanagi T
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1512-5. PubMed ID: 8854793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
    Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
    Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis].
    Mizuno I; Yasui T; Takeyama H; Ishikawa M; Terada J; Mohri N; Ueda T; Sumita N; Kobayashi K; Akamo Y
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1598-601. PubMed ID: 7574769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor effect of liposome-entrapped carboplatin after intraperitoneal administration in rats].
    Yasui T; Mizuno I; Ichino T; Akamo Y; Yamamoto T; Itabashi Y; Saito T; Kurahashi S; Tanimoto N; Yura J
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1753-5. PubMed ID: 1530349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
    Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
    Chen CL; Sun MH; Tan DC; Liang LZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1405-8. PubMed ID: 15566645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
    Lindnér P; Heath D; Howell S; Naredi P; Hafström L
    Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a rat model.
    Pohlen U; Rieger H; Meyer BT; Loddenkemper C; Buhr HJ; Heitland P; Koester HD; Schneider P
    Anticancer Res; 2007; 27(2):809-15. PubMed ID: 17465206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model.
    Hribaschek A; Ridwelski K; Pross M; Meyer F; Kuhn R; Halangk W; Boltze C; Lippert H
    Oncol Rep; 2003; 10(6):1793-8. PubMed ID: 14534698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues].
    Shinohara C; Matsumoto K; Kuriyama M; Adachi H; Ono Y; Higashi H; Furuta T; Ohmoto T
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1163-8. PubMed ID: 8031157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoembolization of the lung improves tumor control in a rat model.
    Schneider P; Kampfer S; Loddenkemper C; Foitzik T; Buhr HJ
    Clin Cancer Res; 2002 Jul; 8(7):2463-8. PubMed ID: 12114454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
    Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M
    Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer.
    Li FR; Yan WH; Guo YH; Qi H; Zhou HX
    Int J Hyperthermia; 2009 Aug; 25(5):383-91. PubMed ID: 19391033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients.
    Oguri T; Isobe T; Mitsuta K; Masuda K; Daga H; Ishikawa N; Fujitaka K; Miyazaki M; Kohno N
    Anticancer Res; 2001; 21(6A):3933-6. PubMed ID: 11911273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
    Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
    Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry.
    Clerico A; Cappelli C; Ragni G; Caroli S; De Ioris MA; Sordi A; Petrucci F; Bocca B; Alimonti A
    Ann Ist Super Sanita; 2006; 42(4):461-8. PubMed ID: 17361071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibility of alpha-tricalcium phosphate (alpha-TCP) particles as a drug carrier for treatment of abdominal carcinomatosis].
    Ueda T; Mizuno I; Yotsuyanagi T; Akamo Y; Mohri N; Terada J; Shibata T; Yamamoto T; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1789-93. PubMed ID: 9382534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.